Gilead Sciences (GILD) CFO Dickinson Sells $469K of Stock

Gilead Sciences, Inc. (NASDAQ:GILD) Chief Financial Officer Andrew D Dickinson sold 3,000 shares of the company on October 15, 2026, according to a Form 4 filing with the SEC. The stock closed at $157.37 on the day of the transaction.

Inside Andrew D Dickinson's Gilead Trade

Dickinson executed the sale at a price of $156.22 per share, totaling roughly $468,660. The transaction was carried out under a pre-arranged Rule 10b5-1 trading plan. Following the sale, the chief financial officer held 161,096 shares, which represents a reduction of about 1.8% in his personal holdings.

Other Institutional Activity in Gilead Sciences

Large investment firms have also adjusted their positions in the biopharmaceutical company recently. Massachusetts Financial Services grew its holdings by 2,058,305 shares, ending with 6,281,609 shares worth about $799.2 million. Dodge & Cox reduced its stake by 2,032,685 shares, leaving it with 24,250,826 shares valued at roughly $3.1 billion. ARS Wealth Advisors Group acquired a new position of 1,458 shares valued at $217,280. Caisse de Depot Et Placement Du Quebec lifted its position by 594,774 shares to hold 1,544,223 shares worth about $195.1 million.

Gilead Sciences, Inc. Stock Down 1.0%

Gilead shares recently traded around $155.84 as of October 17, 2026. That puts the stock down about 1.0% since Dickinson's transaction. The shares trade about 6.5% above their 50-day moving average of $146.33 and sit near their 52-week high of $160.51.

Recent Earnings

Gilead reported trailing twelve-month revenue of $30.5 billion alongside trailing earnings of $2.65 per share in the red. The company's next financial update is scheduled for October 29, 2026.

Dividend

The drug maker distributes an annual dividend rate of $3.28 per share. That payout translates to a dividend yield of 2.1% based on recent share prices.

Insider Buying and Selling at Gilead Sciences, Inc.

Insiders have been active with their shares over the autumn months. Chief Executive Officer Daniel Patrick O'Day sold 15,000 shares on September 1, 2026, for a total value of about $2.2 million. Johanna Mercier, an officer with the firm, sold 3,000 shares on September 15, 2026, worth roughly $432,646. Dickinson also executed an earlier sale on September 15, 2026, parting with 3,000 shares at $145.29 apiece for a total of $435,870. Mercier later completed a planned sale of 3,000 shares on October 15, 2026, valued at $468,660.

Analysts Set New Price Targets

Wall Street firms have updated their outlooks on the stock through October. Truist Securities maintained its buy rating on October 7, 2026, while lifting its target to $158.00 from $150.00. JP Morgan kept an overweight rating while raising its target to $170.00 from $160.00. Morgan Stanley maintained an overweight rating with a target adjusted to $163.00 from $165.00. RBC Capital kept a sector perform rating alongside a target of $126.00. Cantor Fitzgerald kept an overweight rating with a target of $155.00. Analysts hold a consensus buy recommendation on the stock with a mean price target of $159.85.

About Gilead Sciences

Gilead Sciences is a Foster City, California-based biopharmaceutical firm that discovers and markets treatments for severe medical conditions, including therapies for HIV-1 infections such as Biktarvy and Sunlenca. The company employs roughly 17,000 people and carries a market capitalization near $193.7 billion.

Bottom Line

Investors will watch for the company's upcoming earnings report on October 29, 2026, for further updates on financial performance. Insider transactions filed on Form 4 offer a look into how executive leadership manages personal holdings, though planned sales often follow pre-scheduled schedules rather than sudden shifts in outlook.